908P Association of Biomarkers with Response to First-Line (1L) Vibostolimab (Anti-Tigit) Coformulated with Pembrolizumab (vibo/pembro) in Advanced Head and Neck Squamous Cell Carcinoma (HNSCC): Results from KEYVIBE-005
Annals of Oncology(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要